Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Andy Rawstron, Nichola Webster, Surita Dalal, Ruth M de Tute, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen

Blood (2023) 142 (Supplement 1): 632.

https://doi.org/10.1182/blood-2023-187943

Published: 2023

Journal Articles

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Blood (2023) 142 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2023-180527

Published: 2023

Journal Articles

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Blood (2023) 142 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2023-188597

Published: 2023

Journal Articles

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

Talha Munir, Peter Hillmen, MBChB, PhD, Lucy McParland, Dena Cohen, Anna Hockaday, Jamie Oughton, Fabrizio Messina, David Phillips, Jeffrey R. Neilson, FRCP,FRCPath, Nicholas Pemberton, Shankara Paneesha, MD MRCP, FRCPath, Ben Kennedy, MBChB, FRCP, FRCPath, Andy Rawstron, PhD

Blood (2017) 130 (Supplement 1): 3013.

https://doi.org/10.1182/blood.V130.Suppl_1.3013.3013

Published: 2017

Journal Articles

Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up

Andy C Rawstron, BSc, PhD, Dena Howard, Lucy McParland, Ruth Mary de Tute, PhD FRCPath, Laura Collett, David Phillips, Anna Chalmers, Abraham Mullasseril Varghese, Talha Munir, Walter M Gregory, PhD, Rebecca Bishop, BSc, Francesca J Yates, PhD MSci, Kristian Brock, MSc, BSc, Samuel Muñoz-Vicente, Peter Hillmen

Blood (2016) 128 (22): 3226.

https://doi.org/10.1182/blood.V128.22.3226.3226

Published: 2016

Journal Articles

The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring

Andy C Rawstron, Dena Cohen, Ruth Mary De Tute, Lucy McParland, Laura Collett, David Phillips, Anna Chalmers, Abraham Mullasseril Varghese, Talha Munir, Walter M Gregory, Peter Hillmen

Blood (2015) 126 (23): 1717.

https://doi.org/10.1182/blood.V126.23.1717.1717

Published: 2015

Journal Articles

Critical role for Syk in responses to vascular injury

Blood (2011) 118 (18): 5000–5010.

https://doi.org/10.1182/blood-2011-06-360743

Published: 2011

Includes: Supplemental data

Journal Articles

Specific Pharmacological Targeting of the Syk Kinase Activity in Platelets: A Novel, Safe Anti-Thrombotic Strategy

Suzanne Delaney, PhD, Uma Sinha, PhD, Nisha Nanda, PhD, Yibing Yan, PhD, Anjali Pandey, PhD, Stan Hollenbach, Whyte Owen, PhD, David Phillips, PhD, Patrick Andre, Ph.D.

Blood (2008) 112 (11): 409.

https://doi.org/10.1182/blood.V112.11.409.409

Published: 2008

Journal Articles

Specific Inhibition of Syk Is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin’s Lymphoma Cell Lines without Concomitant Inhibition of JAK.

Greg Coffey, Ph.D., Peng Luan, Ph.D., Suzanne Delaney, Ph.D., Anjali Pandey, Ph.D., Zhaozhong Jia, Ph.D., Qing Xu, Ph.D., Shawn Bauer, Ph.D., Yonghong Song, Ph.D., Pamela B. Conley, Ph.D., David Phillips, Ph.D., Uma Sinha, Ph.D.

Blood (2008) 112 (11): 1794.

https://doi.org/10.1182/blood.V112.11.1794.1794

Published: 2008

Journal Articles

Tyrosine Phosphorylation of the Integrin β3 Subunit Regulates β3 Cleavage by Calpain.

Aleksandra Stojanovic, BS, Panagiotis Flevaris, BS, Xiaodong Xi, MD, PhD, Athar Chisti, PhD, David Phillips, PhD, Stephen C.-T. Lam, PhD, Xiaoping Du, MD, PhD

Blood (2006) 108 (11): 1524.

https://doi.org/10.1182/blood.V108.11.1524.1524

Published: 2006

Journal Articles

A Novel Pharmacodynamic Perfusion Chamber Assay Reveals Superior and Unique Antithrombotic Activities of a Direct-Acting P2Y 12 Antagonist, PRT128, Relative to Clopidogrel.

Pamela Conley, PhD, Marzena Jurek, M.S., Gillian Stephens, Ph.D., Ming He, M.S., Alok Finn, M.D., Herman Gold, M.D., Kevin Romanko, D.P.M., Daniel Gretler, M.D., David Phillips, Ph.D., Patrick Andre, Ph.D.

Blood (2006) 108 (11): 900.

https://doi.org/10.1182/blood.V108.11.900.900

Published: 2006

NARROW

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up

The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring

Critical role for Syk in responses to vascular injury

Specific Pharmacological Targeting of the Syk Kinase Activity in Platelets: A Novel, Safe Anti-Thrombotic Strategy

Specific Inhibition of Syk Is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin’s Lymphoma Cell Lines without Concomitant Inhibition of JAK.

Tyrosine Phosphorylation of the Integrin β3 Subunit Regulates β3 Cleavage by Calpain.

A Novel Pharmacodynamic Perfusion Chamber Assay Reveals Superior and Unique Antithrombotic Activities of a Direct-Acting P2Y 12 Antagonist, PRT128, Relative to Clopidogrel.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only